



protein**simple**[™]
Corporate Fact Sheet

ProteinSimple's goal is simply to help researchers gain a better understanding of proteins and their role in disease. The Company's strategy is to power protein research by making it simpler and more quantitative, ultimately revealing new insights into the true nature of proteins. ProteinSimple has built a unique portfolio of protein analysis tools including systems for traditional protein imaging, systems to probe the structure and purity of protein based therapeutics and systems that provide fresh insight into protein signaling. ProteinSimple has over 170 employees, more than 10,000 systems installed around the world and is headquartered in Santa Clara, California.

Products

Protein research has developed tremendously over the last decade, and so has the need for innovative research tools. ProteinSimple is a leader in developing cutting-edge technologies.

- The **NanoPro assay product family** includes the NanoPro 1000 and 100 assay platforms, Compass software suite, and an expanding menu of assay products optimized for the analysis of precious biological samples. Researchers use NanoPro products to study subtle details about critical signaling proteins in disease states such as cancer and diabetes. Because of our systems' extreme detection sensitivity, low-abundance proteins can be accurately measured in samples as small as 25 cells, including sorted cells, fine needle tumor aspirates, micro-dissected tissue sections, and stem cells.
- **iCE280 imaging capillary electrophoresis products** are the acknowledged gold standard for monitoring protein charge heterogeneity, a critical quality control measurement performed during the production of protein-based therapeutics. The Convergent iCE technology accelerates the development of protein therapeutics by providing rapid method development and sample analysis with superior resolution and reproducibility, ultimately leading to earlier biologic regulatory approvals.
- **MFI Micro-Flow Imaging systems** are used by pharmaceutical scientists to characterize and quantify microscopic particles in therapeutic formulations. The world's largest pharmaceutical and biotechnology companies use MFI systems to measure protein aggregates and particulates, air bubbles, silicon oil droplets and foreign particulates in their drug products. MFI offers consistent, precise and highly repeatable results that help our customers meet recent FDA requirements to quantify aggregates and particulates in biotherapeutic formulations.
- The **FluorChem and Alphamager digital imaging systems** feature high-sensitivity imaging for genomic and proteomic research, from entry-level gel documentation systems to premier systems for multiplexed fluorescence and proteomics applications. Our flagship imaging system is the powerful FluorChem M, optimized for ultra-sensitive, quantitative multicolor Western blot analysis.
- Our **ProteomeChip sample preparation products** offer rapid, highly reproducible protein fractionation of complex biological samples — an important prerequisite step for quantitative proteomics measurements. The digital ProteomeChip (dPC) technology can be used as a sample preparation front-end for many protein analysis techniques, including Western blot analysis, mass spectrometry, and our NanoPro platform.
- World-class customer support is a cornerstone of our business. Our technical support and applications support team is available worldwide.



Management Team

- Tim Harkness, President and Chief Executive Officer
- Jason Novi, Vice President of Finance and Chief Financial Officer
- Walter Ausserer, Ph.D., Vice President, General Manager of Biologics
- Trent Basarsky, Ph.D., Vice President of Corporate Development
- Steven Davenport, Vice President of European Sales
- Robert Gavin, Vice President of Product Development
- Wilhelm Lachnit, Ph.D., Vice President of Sales and Service

Board of Directors

- Tim Harkness, President and Chief Executive Officer
- Blaine Bowman, Lead Director, formerly President and Chief Executive Officer of Dionex Corporation
- David L. Barker, Ph.D., formerly Vice President and Chief Scientific Officer of Illumina, Inc. and Amersham Biosciences
- Ron Eastman, Managing Director at Essex Woodlands Health Ventures
- Jack Nielsen, Partner at Novo Ventures
- Jim Woody, M.D., Ph.D., Partner at Latterell Venture Partners, formerly President of Roche Biosciences

Investors: Domain Associates, Essex Woodlands Health Ventures, Latterell Venture Partners, Mitsui Ventures, Novo A/S, Royal Bank of Canada, The Vertical Group, and The Wellcome Trust

Contact: 3040 Oakmead Village Drive, Santa Clara, California 95051
Toll-Free: (888) 607-9697; Tel: +1 (408) 510-5500; Fax: +1 (408) 510-5599;
Email: info@proteinsimple.com; Web: www.proteinsimple.com